STERIS (STE) Stock Price, News & Analysis

Company Overview

STERIS plc (NYSE: STE) is a global provider of products and services designed to support infection prevention, sterilization, surgical procedures and other critical healthcare and life sciences activities. The company serves hospitals, ambulatory surgery centers, dental practices, pharmaceutical and biotechnology manufacturers, medical device companies, and research organizations.

Its offerings include sterilizers, washers, surgical tables and lights, operating-room equipment, endoscopy products, infection-prevention consumables, and related maintenance and technical services. STERIS also provides contract sterilization and laboratory testing services, as well as equipment and process solutions for pharmaceutical, biotechnology and medical device manufacturing.

Founded in 1987, STERIS has expanded through organic growth and acquisitions, including its 2015 combination with Synergy Health. The company is incorporated in Ireland and maintains a broad international presence, serving customers across North America, Europe, Asia-Pacific and other global markets.

Key Stats

• Today's Range: $211.49 to $214.31
• 50-Day Range: $208.15 to $238.93
• 52-Week Range: $195.14 to $269.44
• Volume: 45,984 shs
• Average Volume: 772,577 shs
• Market Capitalization: $20.80 billion
• P/E Ratio: 26.08
• Dividend Yield: 1.29%
• Price Target: $271.33
• Consensus Rating: Moderate Buy

STERIS Stock Analysis - MarketRank™

STERIS scored higher than 98% of companies evaluated by MarketBeat, and ranked 6th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

STERIS has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

STERIS has a consensus price target of $271.33, representing about 26.1% upside from its current price of $215.18.

Amount of Analyst Coverage

STERIS has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.64%

Earnings Growth

Earnings for STERIS are expected to grow by 10.64% in the coming year, from $11.09 to $12.27 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of STERIS is 26.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.09.

Price to Earnings Ratio vs. Sector

The P/E ratio of STERIS is 26.31, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.78.

Price to Book Value per Share Ratio

STERIS has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.40% of the float of STERIS has been sold short.

Short Interest Ratio / Days to Cover

STERIS has a short interest ratio ("days to cover") of 2.89, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in STERIS has recently decreased by 26.68%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

STERIS pays a meaningful dividend of 1.26%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

STERIS has been increasing its dividend for 20 years.

Dividend Coverage

The dividend payout ratio of STERIS is 33.74%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, STERIS will have a dividend payout ratio of 22.49% next year. This indicates that STERIS will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.97

News Sentiment

STERIS has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for STERIS this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 2 people have added STERIS to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, STERIS insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,253,764.00 in company stock.

Percentage Held by Insiders

1.12% of the stock of STERIS is held by insiders.

Percentage Held by Institutions

94.69% of the stock of STERIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 6/26 Dividend: 6/08/2026
• Ex-Dividend for 6/26 Dividend: 6/08/2026
• Dividend Payable: 6/26/2026
• Last Earnings: 8/05/2026
• Record date for 9/25 Dividend: 9/04/2026
• Ex-Dividend for 9/25 Dividend: 9/04/2026
• Today: 9/10/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/15/2026
• Dividend Payable: 9/25/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:STE
• CIK: 1757898
• Web: www.steris.com
• Phone: +35312322000
• Fax: 440-639-4457
• Employees: 17,937
• Year Founded: 1985

Price Target and Rating

• Average Price Target for STERIS: $271.33
• High Price Target: $275.00
• Low Price Target: $269.00
• Potential Upside/Downside: +26.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $8.18
• Trailing P/E Ratio: 26.31
• Forward P/E Ratio: 19.40
• P/E Growth: N/A
• Net Income: $782.30 million
• Net Margins: 13.34%
• Pretax Margin: 18.03%
• Return on Equity: 14.34%
• Return on Assets: 9.66%

Debt

• Debt-to-Equity Ratio: 0.23
• Current Ratio: 1.91
• Quick Ratio: 1.35

Sales & Book Value

• Annual Sales: $5.94 billion
• Price / Sales: 3.53
• Cash Flow: $14.96 per share
• Price / Cash Flow: 14.38
• Book Value: $73.39 per share
• Price / Book: 2.93

Miscellaneous

• Outstanding Shares: 97,500,000
• Free Float: 96,408,000
• Market Cap: $20.98 billion
• Optionable: Optionable
• Beta: 0.91